Brief: IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics
24/11/2021 06:08
Nov 24 (Reuters) - IX Biopharma Ltd IXBI.SI :
* ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH SEELOS
THERAPEUTICS
* WILL RECEIVE US$9 MILLION UPFRONT PAYMENT TO BE SATISFIED
IN
CASH AND SHARES
* ALSO ELIGIBLE FOR UP TO US$239 MILLION IN MILESTONE
PAYMENTS AS
PART OF DEAL
Source text for Eikon: ID:nSN4DNx5y
Further company coverage: IXBI.SI
((Reuters.Briefs@thomsonreuters.com;))
Recent news on IX Biopharma
See all newsBrief: Ix Biopharma Confirms Orion Not Yet Obtained Licence From Nevada State Board Of Pharmacy
Brief: Ix Biopharma Says U.S. Govt Opens Emergency Pathway, Clears Path For Wafermine Application For EUA
Brief: IX Biopharma Says Co Will Undertake An Internal Restructuring Of Its Consumer Business
Brief: IX Biopharma To Issue 1 MLN New Shares To Anson Properties At S$0.4215 Per Share
Brief: IX Biopharma Says US Government Awards US$41 MLN Contract To Fund Development Of Wafermine